Identification of Host PDZ-Based Interactions with the SARS-CoV-2 E Protein in Human Monocytes.

IL-16 PDZ SARS-CoV-2 ZO-2 envelope (E) protein innate immune response monocyte syntenin

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
14 Aug 2023
Historique:
received: 01 07 2023
revised: 01 08 2023
accepted: 06 08 2023
medline: 28 8 2023
pubmed: 26 8 2023
entrez: 26 8 2023
Statut: epublish

Résumé

Proteins containing PDZ (post-synaptic density, PSD-95/disc large, Dlg/zonula occludens, ZO-1) domains assemble signaling complexes that orchestrate cell responses. Viral pathogens target host PDZ proteins by coding proteins containing a PDZ-binding motif (PBM). The presence of a PBM in the SARS-CoV-2 E protein contributes to the virus's pathogenicity. SARS-CoV-2 infects epithelia, but also cells from the innate immune response, including monocytes and alveolar macrophages. This process is critical for alterations of the immune response that are related to the deaths caused by SARS-CoV-2. Identification of E-protein targets in immune cells might offer clues to understanding how SARS-CoV-2 alters the immune response. We analyzed the interactome of the SARS-CoV-2 E protein in human monocytes. The E protein was expressed fused to a GFP tag at the amino terminal in THP-1 monocytes, and associated proteins were identified using a proteomic approach. The E-protein interactome provided 372 partners; only 8 of these harbored PDZ domains, including the cell polarity protein ZO-2, the chemoattractant IL-16, and syntenin. We addressed the expression and localization of the identified PDZ proteins along the differentiation of primary and THP-1 monocytes towards macrophages and dendritic cells. Our data highlight the importance of identifying the functions of PDZ proteins in the maintenance of immune fitness and the viral alteration of inflammatory response.

Identifiants

pubmed: 37628973
pii: ijms241612793
doi: 10.3390/ijms241612793
pmc: PMC10454406
pii:
doi:

Substances chimiques

Transcription Factors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : European Commission to IM; Spanish Ministry of Science and Innovation (MINECO) to AAF and IM, the Jesus Serra Foundation to AAF; and the Mexican National Council of Science and Technology (CONACyT) to TSM.
ID : European Commission - Next Generation EU (Regulation EU 2020/2094) through CSIC's Global Health Platform (PTI Salud Global); and grants from the Spanish Ministry of Sciece; MINECO PID2019-108357RB-I00/10.13039/501100011033); CONACyT CB2015-250579.

Références

Pathobiology. 1998;66(3-4):128-30
pubmed: 9693312
PLoS Biol. 2008 Sep 30;6(9):e239
pubmed: 18828675
Molecules. 2020 Oct 26;25(21):
pubmed: 33114686
Biotechnol J. 2008 Mar;3(3):370-7
pubmed: 18064608
FEBS J. 2021 Sep;288(17):5148-5162
pubmed: 33864728
J Infect Dis. 2021 Mar 3;223(5):785-795
pubmed: 33277988
Nat Rev Drug Discov. 2021 May;20(5):384-405
pubmed: 33692549
Viruses. 2021 Oct 28;13(11):
pubmed: 34834984
Biomed Pharmacother. 2023 Mar;159:114242
pubmed: 36652729
Adv Ther (Weinh). 2019 Jul;2(7):1800143
pubmed: 32313833
J Leukoc Biol. 2000 Jun;67(6):757-66
pubmed: 10857846
Nat Cell Biol. 2016 Nov;18(11):1244-1252
pubmed: 27694890
Emerg Microbes Infect. 2020 Dec;9(1):221-236
pubmed: 31987001
Immunity. 2005 Jun;22(6):737-48
pubmed: 15963788
Nature. 2022 Jun;606(7914):576-584
pubmed: 35385861
Biochem J. 2011 Oct 15;439(2):195-205
pubmed: 21954943
Oncogene. 2001 Nov 26;20(54):7874-87
pubmed: 11753670
Sci Rep. 2021 Feb 18;11(1):4083
pubmed: 33602969
J Virol. 2011 Oct;85(20):10639-48
pubmed: 21849460
J Neuroinflammation. 2023 Feb 9;20(1):30
pubmed: 36759861
Eur J Immunol. 2013 May;43(5):1185-94
pubmed: 23436244
Mol Biol Cell. 2009 Sep;20(17):3930-40
pubmed: 19605556
Virology. 2015 Nov;485:330-9
pubmed: 26331680
Int J Mol Sci. 2022 Jun 24;23(13):
pubmed: 35806015
Cell. 1998 Sep 18;94(6):761-71
pubmed: 9753323
PLoS Pathog. 2014 Aug 14;10(8):e1004320
pubmed: 25122212
Virology. 2006 Jun 5;349(2):264-75
pubmed: 16507314
Front Microbiol. 2020 Sep 03;11:2086
pubmed: 33013759
J Virol. 2011 Jun;85(12):5794-803
pubmed: 21450821
J Cell Biol. 2019 Mar 4;218(3):742-756
pubmed: 30598480
Biochem Biophys Res Commun. 2005 Aug 5;333(3):896-907
pubmed: 15963458
J Virol. 2010 Oct;84(20):10708-18
pubmed: 20686040
J Leukoc Biol. 2018 Apr;103(4):731-738
pubmed: 29345359
Int J Mol Sci. 2019 Aug 24;20(17):
pubmed: 31450555
Science. 2001 Aug 10;293(5532):1136-8
pubmed: 11498591
Am J Respir Cell Mol Biol. 1995 Dec;13(6):738-47
pubmed: 7576712
Front Microbiol. 2021 Sep 22;12:736449
pubmed: 34630361
Int Immunopharmacol. 2014 Nov;23(1):37-45
pubmed: 25130606
Nature. 2000 Feb 10;403(6770):676-80
pubmed: 10688207
Mol Biol Cell. 2010 Nov 15;21(22):3838-52
pubmed: 20861307
Front Immunol. 2022 Sep 26;13:979188
pubmed: 36225942
Biochem Soc Trans. 2023 Feb 27;51(1):415-426
pubmed: 36606695
PLoS One. 2021 Jun 9;16(6):e0251955
pubmed: 34106957
mBio. 2020 Jun 16;11(3):
pubmed: 32546618
Nat Genet. 2017 Apr;49(4):515-526
pubmed: 28191889
Viruses. 2022 Oct 06;14(10):
pubmed: 36298757
J Neurosci. 2002 Feb 1;22(3):803-14
pubmed: 11826110
Cell Res. 2021 Aug;31(8):847-860
pubmed: 34112954
Methods Mol Biol. 2021;2256:217-236
pubmed: 34014525
J Biol Chem. 2021 Jan-Jun;296:100111
pubmed: 33229438
Int J Mol Sci. 2019 Aug 26;20(17):
pubmed: 31454940
Mol Biol Cell. 2007 Dec;18(12):4826-36
pubmed: 17881732
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Nat Commun. 2021 Jun 8;12(1):3433
pubmed: 34103506
J Immunol Res. 2020 Apr 30;2020:5649790
pubmed: 32411799
J Struct Biol X. 2020;4:100022
pubmed: 32289118
Mol Cell Biol. 2007 Nov;27(21):7574-81
pubmed: 17724087
Viruses. 2020 Jan 03;12(1):
pubmed: 31947814
J Leukoc Biol. 2020 Sep;108(3):883-893
pubmed: 32293058
Sci STKE. 2003 Apr 22;2003(179):RE7
pubmed: 12709532
G3 (Bethesda). 2020 Sep 2;10(9):3399-3402
pubmed: 32763951
FASEB J. 2019 Oct;33(10):10607-10617
pubmed: 31336050
Cell Host Microbe. 2016 Mar 9;19(3):336-48
pubmed: 26962944
J Infect Dis. 2021 Aug 2;224(3):395-406
pubmed: 33493287
J Immunol. 2013 Aug 1;191(3):1413-27
pubmed: 23817423
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Neuron. 2001 Aug 2;31(2):289-303
pubmed: 11502259
Sci Rep. 2016 Aug 31;6:32337
pubmed: 27578500

Auteurs

Antonia Ávila-Flores (A)

Department of Immunology and Oncology, Spanish National Centre for Biotechnology, 28049 Madrid, Spain.

Juan José Sánchez-Cabezón (JJ)

Department of Immunology and Oncology, Spanish National Centre for Biotechnology, 28049 Madrid, Spain.

Ane Ochoa-Echeverría (A)

Department of Immunology and Oncology, Spanish National Centre for Biotechnology, 28049 Madrid, Spain.

Ana I Checa (AI)

Department of Immunology and Oncology, Spanish National Centre for Biotechnology, 28049 Madrid, Spain.

Jorge Rosas-García (J)

Laboratory of Transcriptomics and Molecular Immunology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico.

Mariana Téllez-Araiza (M)

Laboratory of Transcriptomics and Molecular Immunology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico.

Sara Casado (S)

Department of Immunology and Oncology, Spanish National Centre for Biotechnology, 28049 Madrid, Spain.

Rosa Liébana (R)

Department of Immunology and Oncology, Spanish National Centre for Biotechnology, 28049 Madrid, Spain.

Teresa Santos-Mendoza (T)

Laboratory of Transcriptomics and Molecular Immunology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico.

Isabel Mérida (I)

Department of Immunology and Oncology, Spanish National Centre for Biotechnology, 28049 Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH